Tafasitamab (XmAb5574) 是一种 Fc 修饰的人源化单克隆抗体，可与人 B 细胞表面抗原 CD19 结合。
货号:ajcx39572
CAS:1422527-84-1
分子式:N/A
分子量：N/A
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19[1][2].

Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis[1][2].

Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models[1].

[1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29.
[2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res